{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:51:21Z","timestamp":1791960681462,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.ophtha.2011.08.032","type":"journal-article","created":{"date-parts":[[2011,12,9]],"date-time":"2011-12-09T01:49:04Z","timestamp":1323395344000},"page":"327-332","source":"Crossref","is-referenced-by-count":26,"title":["Analysis of Outcomes for Intravitreal Bevacizumab in the Treatment of Choroidal Neovascularization Secondary to Ocular Histoplasmosis"],"prefix":"10.1016","volume":"119","author":[{"given":"Douglas A.","family":"Cionni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn A.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Riemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Sisk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Hutchins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2011.08.032_bib1","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00006982-198101030-00021","article-title":"Long-term follow-up of ocular histoplasmosis treated by argon laser photocoagulation","volume":"1","author":"Olk","year":"1981","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2011.08.032_bib2","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1001\/archopht.1987.01060110045029","article-title":"Krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis: results of a randomized clinical trial","volume":"105","year":"1987","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2011.08.032_bib3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0039-6257(77)90055-8","article-title":"Ocular histoplasmosis: clinicopathologic correlation of 3 cases","volume":"22","author":"Meredith","year":"1977","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ophtha.2011.08.032_bib4","first-page":"1","article-title":"Epidemiologic characteristics of presumed ocular histoplasmosis","volume":"119","author":"Ganley","year":"1973","journal-title":"Acta Ophthalmol Suppl"},{"key":"10.1016\/j.ophtha.2011.08.032_bib5","first-page":"72","article-title":"Histopathology of presumed ocular histoplasmosis","volume":"1","author":"Makley","year":"1977","journal-title":"Palestra Oftalmol Panam"},{"key":"10.1016\/j.ophtha.2011.08.032_bib6","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1136\/bjo.83.5.535","article-title":"Aetiological study of the presumed ocular histoplasmosis syndrome in the Netherlands","volume":"83","author":"Ongkosuwito","year":"1999","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2011.08.032_bib7","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1136\/bjo.73.7.528","article-title":"Presumed ocular histoplasmosis syndrome and linear streak lesions","volume":"73","author":"Bottoni","year":"1989","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2011.08.032_bib8","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1001\/archopht.121.11.1551","article-title":"Detection of Histoplasma capsulatum DNA in lesions of chronic ocular histoplasmosis syndrome","volume":"121","author":"Spencer","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2011.08.032_bib9","first-page":"114","article-title":"The natural history of non-disciform ocular histoplasmosis","volume":"12","author":"Ganley","year":"1977","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.ophtha.2011.08.032_bib10","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/archopht.1983.01040020349002","article-title":"Argon laser photocoagulation for ocular histoplasmosis: results of a randomized clinical trial","volume":"101","year":"1983","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2011.08.032_bib11","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0161-6420(02)01103-X","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series","volume":"109","author":"Saperstein","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2011.08.032_bib12","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.ophtha.2004.02.014","article-title":"Photodynamic therapy with verteporfin in ocular histoplasmosis: uncontrolled, open-label 2-year study","volume":"111","author":"Rosenfeld","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2011.08.032_bib13","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ophtha.2007.08.045","article-title":"Long-term follow-up of surgical removal of extensive peripapillary choroidal neovascularization in presumed ocular histoplasmosis syndrome","volume":"115","author":"Almony","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2011.08.032_bib14","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.ajo.2007.12.030","article-title":"Intravitreal bevacizumab for choroidal neovascularization in ocular histoplasmosis","volume":"145","author":"Schadlu","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2011.08.032_bib15","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ajo.2008.05.024","article-title":"Intravitreal bevacizumab in inflammatory ocular neovascularization","volume":"146","author":"Mansour","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2011.08.032_bib16","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ajo.2009.06.010","article-title":"Bevacizumab in inflammatory eye disease","volume":"148","author":"Lott","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2011.08.032_bib17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ajo.2007.09.025","article-title":"Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related macular degeneration","volume":"145","author":"Nguyen","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2011.08.032_bib18","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/IAE.0b013e3181babdf1","article-title":"Intravitreal bevacizumab for choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome","volume":"29","author":"Erlich","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2011.08.032_bib19","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1097\/IAE.0b013e31815e9834","article-title":"Intravitreal bevacizumab (Avastin) injection as primary treatment of inflammatory choroidal neovascularization","volume":"27","author":"Adan","year":"2007","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2011.08.032_bib20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ajo.2006.11.037","article-title":"Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization in pathologic myopia: a long-term follow-up study","volume":"143","author":"Pece","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2011.08.032_bib21","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00006982-200306000-00003","article-title":"Ocular photodynamic therapy with verteporfin for choroidal neovascularization secondary to ocular histoplasmosis syndrome","volume":"23","author":"Busquets","year":"2003","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2011.08.032_bib22","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/j.ophtha.2006.04.039","article-title":"Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized study","volume":"113","author":"Arias","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2011.08.032_bib23","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0161-6420(02)01998-X","article-title":"Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial\u2014VIP report no. 3","volume":"110","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2011.08.032_bib24","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S0161-6420(03)00466-4","article-title":"Photodynamic therapy of idiopathic and inflammatory choroidal neovascularization in young adults","volume":"110","author":"Rogers","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2011.08.032_bib25","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ajo.2009.03.023","article-title":"Long-term visual outcomes of intravitreal bevacizumab in inflammatory ocular neovascularization","volume":"148","author":"Mansour","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2011.08.032_bib26","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/IAE.0b013e3181a46a8a","article-title":"Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration","volume":"29","author":"Bakri","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2011.08.032_bib27","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ophtha.2008.12.057","article-title":"Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration","volume":"116","author":"Kaiser","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2011.08.032_bib28","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bjo.2009.159343","article-title":"Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration","volume":"94","author":"Costagliola","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2011.08.032_bib29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","article-title":"A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study","volume":"148","author":"Lalwani","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2011.08.032_bib30","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ophtha.2008.10.029","article-title":"Economic implications of current age-related macular degeneration treatments","volume":"116","author":"Smiddy","year":"2009","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642011007974?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642011007974?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T20:56:15Z","timestamp":1543352175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642011007974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0161642011007974"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2011.08.032","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}